These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intralesional curettage, with phenol and cement as adjuvants, for low-grade intramedullary chondrosarcoma of the long bones.
    Author: Di Giorgio L, Touloupakis G, Vitullo F, Sodano L, Mastantuono M, Villani C.
    Journal: Acta Orthop Belg; 2011 Oct; 77(5):666-9. PubMed ID: 22187844.
    Abstract:
    The authors conducted a retrospective study on 23 patients (12 females and 11 males) with low-grade intramedullary chondrosarcoma of a long bone, treated with intralesional curettage, phenolization and cementation. The use of phenol was supported by an in vitro study, the use of bone cement by clinical studies. A consensus has been growing that this type of tumours should be treated less aggressively. The average age of the patients was 445 years (range: 29 to 71). The mean follow-up period was 6.2 years (range: 2.5 to 11 years). After 6 months the average Musculoskeletal Tumor Society (MSTS) score was 76.8% of 30, the best possible score (range: 61% to 87%). After 12 months this score increased to 89.8% (range: 63% to 100%). Complications were: one recurrence (43%), treated with a tumour prosthesis, and 3 fractures (13%). The authors strongly support this new technique, all the more as it still allows for a more radical approach, if necessary. They stress the importance of a strict follow-up by a multidisciplinary team, in order to treat local recurrences and (rarely) metastases.
    [Abstract] [Full Text] [Related] [New Search]